Shares in Osprey Medical soared after record sales of its devices to protect patients from the harmful effects of X-ray dye.
A short time ago, the shares were up almost 32% to 29 cents.
Sales of the AVERT and DyeVert systems were up 45% in the second quarter of 2016.
The pilot sales territory in San Antonio, Texas, was cash-flow breakeven in June with 65% of local hospitals buying from Osprey. The average selling price of DyeVert is $US355.
“Osprey has now recorded seven consecutive quarters of growth in units sold and samples, reflecting a strong endorsement from the cardiovascular physician community of Osprey’s dye reduction technologies,” says CEO Mike McCormick.
The technology reduces the amount of X-ray contrast dye injected into patients, protecting the kidneys. Heart and leg vessels imagining requires the injection of x-ray dye which is then cleared by the kidney.
Osprey has its operations in Minnesota.